Search results for " Proportional Hazards Models"

showing 10 items of 43 documents

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort

2021

AbstractAim of the study was to evaluate possible associations between cognitive dysfunctions and development of Levodopa Induced Dyskinesia (LID). PD patients from the Parkinson’s disease Cognitive impairment Study cohort who underwent a baseline and follow-up neuropsychological evaluations were enrolled. Mild Cognitive Impairment (PD-MCI) was diagnosed according to MDS level II criteria. The following cognitive domains were evaluated: episodic memory, attention, executive function, visuo-spatial function and language. A domain was considered as impaired when the subject scored 2 standard deviation below normality cut-off values in at least one test for each domain. Levodopa equivalent dos…

Male0301 basic medicineDyskinesia Drug-InducedLevodopamedicine.medical_specialtyParkinson's diseaseScienceNeuropsychological TestsSeverity of Illness IndexArticleCohort StudiesLevodopaExecutive Function03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansAttentionCognitive DysfunctionLongitudinal StudiesAgedProportional Hazards ModelsLevodopa-induced dyskinesiaMultidisciplinarybusiness.industryQRNeuropsychologyParkinson DiseaseCognitionMiddle Agedmedicine.diseaseAged Attention Cognitive Dysfunction Cohort Studies Dyskinesia Drug-Induced Executive Function Female Humans Levodopa Longitudinal Studies Male Middle Aged Neuropsychological Tests Parkinson Disease Proportional Hazards Models Severity of Illness Index030104 developmental biologyNeurologyRisk factorsDyskinesiaCohortMedicineFemalemedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugCohort studyScientific Reports
researchProduct

Fried potato consumption is associated with elevated mortality: an 8-y longitudinal cohort study

2017

Background: Few studies have assessed the association between potato consumption and mortality. Objective: We investigated whether potato consumption (including fried and unfried potatoes) is associated with increased premature mortality risk in a North American cohort. Design: A longitudinal analysis included 4440 participants aged 45-79 y at baseline with an 8-y follow-up from the Osteoarthritis Initiative cohort study. Potato consumption (including fried and unfried potatoes) was analyzed by using a Block Brief 2000 food-frequency questionnaire and categorized as ≤1 time/mo, 2-3 times/mo, 1 time/wk, 2 times/wk, or ≥3 times/wk. Mortality was ascertained through validated cases of death. T…

Male0301 basic medicineGerontologyMedicine (miscellaneous)0302 clinical medicineRisk FactorsCause of DeathMedicineCookingLongitudinal StudiesProspective Studies030212 general & internal medicineMortality; Osteoarthritis Initiative; Potato; Risk factor; Aged; Cooking; Diet Surveys; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Plant Tubers; Proportional Hazards Models; Prospective Studies; Risk Factors; Cause of Death; Diet; Feeding Behavior; Solanum tuberosum; Medicine (miscellaneous); Nutrition and DieteticsLongitudinal cohortProspective cohort studyCause of deathMortality; Osteoarthritis Initiative; Potato; Risk factor; Medicine (miscellaneous); Nutrition and DieteticsNutrition and Dieteticsmortality potato risk factor Osteoarthritis Initiative.Confoundingfood and beveragesMiddle AgedPlant Tubersrisk factorOsteoarthritis InitiativepotatoFemalePotatoCohort studyDiet SurveysOsteoarthritis Initiative.03 medical and health sciencesAnimal scienceJournal ArticleHumansMortalityRisk factorAgedProportional Hazards ModelsSolanum tuberosumConsumption (economics)030109 nutrition & dieteticsProportional hazards modelbusiness.industryfungiFeeding BehaviormortalityDietRisk factorbusinessFollow-Up StudiesThe American Journal of Clinical Nutrition
researchProduct

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

2016

Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; BACKGROUND Chronic graft-versus-host disease (GVHD) is the leading cause of later illness and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that the inclusion of antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning regimen for patients with acute leukemia would result in a significant reduction in chronic GVHD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-identical sibling. METHODS We conducted a prospective, multicenter, open-label, randomized phase 3 study of ATG as part of …

Male:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Proportional Hazards Models [Medical Subject Headings]T-LymphocytesPhases of clinical researchGraft vs Host Disease:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]Linfocitos t:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Immunosuppressive Agent0302 clinical medicineTrasplante homólogoEstudios prospectivosMedicineCumulative incidenceProspective StudiesProspective cohort studyChildTransplantation Homologou:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Immune Sera::Antilymphocyte Serum [Medical Subject Headings]Acute leukemia:Anatomy::Cells::Blood Cells::Leukocytes::Leukocytes Mononuclear::Lymphocytes::T-Lymphocytes [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [Medical Subject Headings]:Named Groups::Persons::Age Groups::Child::Child Preschool [Medical Subject Headings]Medicine (all)IncidenceSuero antilinfocíticoGeneral MedicineMiddle AgedModelos de riesgos proporcionales3. Good healthHumanosSurvival Rate030220 oncology & carcinogenesis:Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings]Child PreschoolFemale:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents [Medical Subject Headings]Immunosuppressive AgentsHumanHomologousAdultmedicine.medical_specialty:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings]:Named Groups::Persons::Age Groups::Adult::Young Adult [Medical Subject Headings]AdolescentEnfermedad injerto contra huéspedDisease-Free Survival03 medical and health sciencesYoung AdultInternal medicine:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]HumansTransplantation HomologousSupervivencia sin enfermedadPreschoolSurvival rate:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survival [Medical Subject Headings]:Named Groups::Persons::Age Groups::Child [Medical Subject Headings]Antilymphocyte SerumProportional Hazards ModelsTransplantationbusiness.industryEnfermedad crónicamedicine.diseaseInmunosupresoresAnti-thymocyte globulinSurgeryTransplantation:Diseases::Immune System Diseases::Graft vs Host Disease [Medical Subject Headings]Prospective Studie:Analytical Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures Operative::Transplantation::Transplantation Homologous [Medical Subject Headings]Graft-versus-host diseaseT-Lymphocyte:Check Tags::Female [Medical Subject Headings]Chronic DiseaseProportional Hazards ModelAdolescent; Adult; Antilymphocyte Serum; Child; Child Preschool; Chronic Disease; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Survival Rate; T-Lymphocytes; Transplantation Homologous; Young Adult; Medicine (all)business030215 immunology
researchProduct

Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study

2021

This international, prospective, cohort study enrolled 20 006 adult (≥18 years) patients from 466 hospitals in 61 countries with 15 cancer types, who had a decision for curative surgery during the COVID-19 pandemic and were followed up until the point of surgery or cessation of follow-up (Aug 31, 2020). Average national Oxford COVID-19 Stringency Index scores were calculated to define the government response to COVID-19 for each patient for the period they awaited surgery, and classified into light restrictions (index 60). The primary outcome was the non-operation rate (defined as the proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models wer…

MaleCOVID-19 COVIDSURG COVIDSURG CANCEROutcome AssessmentIMPACTSettore MED/18 - CHIRURGIA GENERALEBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Surgery.surgeryCancer surgeryNeoplasms/classificationBIOMEDICINA I ZDRAVSTVO. Javno zdravstvo i zdravstvena zaštita.Surgical oncologyNeoplasmsAcute careCOVID-19 - epidemiologyOutcome Assessment Health CareMedicine and Health Sciences80 and overGlobal healthtimingProspective StudiesUK610 Medicine & healthProspective cohort studyCOVID-19/epidemiologyCOVIDAged 80 and overBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Oncology.BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Kirurgija.Hazard ratioArticlesMiddle AgedOncologyAdult; Aged; Aged 80 and over; Communicable Disease Control; COVID-19; Female; Humans; Male; Middle Aged; Neoplasms; Outcome Assessment Health Care; Proportional Hazards Models; Prospective Studies; SARS-CoV-2; Time-to-Treatment; Withholding Treatment/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalecancer surgeryCovid-19Life Sciences & BiomedicineMENTAL-HEALTHmental healthCohort studyHumanAdultmedicine.medical_specialtydelay3122 CancersCOVID-19 - prevention and control610 Medicine & healthCOVIDSurg CollaborativeNOTime-to-TreatmentSDG 3 - Good Health and Well-beingLockdownmedicineHumanscancer1112 Oncology and CarcinogenesisOncology & CarcinogenesisElective surgeryLS7_4Proportional Hazards ModelsAgedScience & Technologybusiness.industrySARS-CoV-2Public healthGeneral surgeryBIOMEDICINE AND HEALTHCARE. Public Health and Health Care.COVID-193126 Surgery anesthesiology intensive care radiologyHealth CareCommunicable Disease Control/legislation & jurisprudenceProspective StudieWithholding TreatmentCOVID-19; delay; SARS-CoV-2; surgery; timing; cancer surgery;COVID-19 ; lockdowns ; cancer surgeryCommunicable Disease ControlBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Onkologija.Proportional Hazards ModelNeoplasmbusiness
researchProduct

Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

2023

Abstract Background We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients. Methods The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admiss…

MaleEpidemiologyMESH: HospitalizationMESH: Proportional Hazards ModelsMESH: Risk FactorsRisk FactorsMESH: Childcohort studyMESH: COVID-19HumansMESH: SARS-CoV-2ChildProportional Hazards ModelsMESH: HumansMESH: Middle AgedSARS-CoV-2COVID-19risk of deathGeneral MedicineMiddle AgedCOVID-19; SARS-CoV-2; co-morbidities; cohort study; risk of death; symptoms; treatmentsMESH: MaleHospitalizationIntensive Care Unitsco-morbiditiestreatmentssymptomsMESH: Intensive Care Units[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCOVID-19/therapy
researchProduct

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are creat…

2009

Contains fulltext : 80963.pdf (Publisher’s version ) (Open Access) BACKGROUND: The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy. METHODS: We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretrovir…

MaleInfectious diseases and international health [NCEBP 13]Lymphoma030312 virologyEsophageal candidiasisCohort Studies0302 clinical medicineInterquartile range030212 general & internal medicineAIDS-RelatedLymphoma AIDS-Related0303 health sciencesMortality rateProgressive multifocal leukoencephalopathyHazard ratioPrognosis3. Good healthPathogenesis and modulation of inflammation [N4i 1]Infectious DiseasesCombinationDrug Therapy CombinationFemaleInfection and autoimmunity [NCMLS 1]HumanMicrobiology (medical)Adultmedicine.medical_specialtyPrognosiAnti-HIV Agentsantiretroviral therapyInfectious DiseaseArticleAIDS-Related Opportunistic Infection03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)Drug TherapyInternal medicinemedicineHumansAIDS-defining eventProportional Hazards ModelsAIDS-Related Opportunistic Infections/diagnosis/ mortality; Acquired Immunodeficiency Syndrome/complications/diagnosis/drug; therapy/ mortality; Adult; Anti-HIV Agents/ therapeutic use; Cohort Studies; Drug Therapy; Combination; Female; Humans; Lymphoma; AIDS-Related/diagnosis/mortality; Male; Prognosis; Proportional Hazards ModelsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic Infectionsbusiness.industryProportional hazards modelPoverty-related infectious diseases [N4i 3]Anti-HIV Agentmedicine.diseasemortalityConfidence intervalImmunologyProportional Hazards ModelCohort Studiebusiness
researchProduct

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

2018

In this independent, multicenter, retrospective study, we investigated the short-term persistence to treatment with first-line self-injectable or oral disease-modifying treatments (DMTs) in patients with relapsing–remitting multiple sclerosis. Data of patients regularly attending 21 Italian MS Centres who started a self-injectable or an oral DMT in 2015 were collected to: (1) estimate the proportion of patients discontinuing the treatment; (3) explore reasons for discontinuation; (3) identify baseline predictors of treatment discontinuation over a follow-up period of 12 months. We analyzed data of 1832 consecutive patients (1289 women, 543 men); 374 (20.4%) of them discontinued the prescrib…

MaleInjectionTime FactorsPatient Dropoutdisease-modifying therapies; multiple sclerosis; outcome measurement; persistence to treatment; quality of lifeAdministration OralSelf AdministrationSex FactorKaplan-Meier EstimateRelapsing-Remittingmultiple sclerosisImmunologic Factor0302 clinical medicineQuality of lifeRetrospective StudieRisk FactorsMedicine030212 general & internal medicineDisease-modifying therapiedisease-modifying therapiesDisease-modifying therapies Multiple sclerosis Outcome measurement Persistence to treatment Quality of life Administration Oral Adult; Female Follow-Up Studies Humans Immunologic Factors Injections Kaplan-Meier EstimateMale Multiple Sclerosis Relapsing-Remitting Patient Dropouts Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Self Administration Sex Factors Time FactorsHazard ratioPrognosisNeurologyTolerabilityAdministrationSettore MED/26 - NeurologiaFemaleoutcome measurementHumanOralAdultmedicine.medical_specialtyPatient DropoutsTime FactorPrognosiFollow-Up StudieInjections03 medical and health sciencesRoute of administrationMultiple Sclerosis Relapsing-RemittingSex FactorsInternal medicineHumansImmunologic FactorsMultiple sclerosiAdverse effectProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelRisk FactorRetrospective cohort studyDiscontinuationDisease-modifying therapies; Multiple sclerosis; Outcome measurement; Persistence to treatment; Quality of life; Administration Oral; Adult; Female; Follow-Up Studies; Humans; Immunologic Factors; Injections; Kaplan-Meier Estimate; Male; Multiple Sclerosis Relapsing-Remitting; Patient Dropouts; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Self Administration; Sex Factors; Time Factorsquality of lifeProportional Hazards Modelpersistence to treatmentNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of neurology
researchProduct

Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry)

2017

IF 3.398; International audience; The prognosis of patients with acute myocardial infarction (AMI) has notably improved in the past 20 years. Using the French Registry of ST-Elevation and Non-ST-elevation Myocardial Infarction (FAST-MI) 2010 registry, we investigated whether previous manifestations of atherosclerotic disease (i.e., previous MI, or a history of any form of atherosclerotic disease) are at truly increased risk compared with those in whom AMI is the first manifestation of the disease. FAST-MI 2010 is a nationwide French registry including 3,079 patients with AMI, among whom 1,062 patients had a history of cardiovascular atherosclerotic disease and 498 patients had a history of …

MaleMESH : Atherosclerosismedicine.medical_treatmentMESH : MortalityMyocardial InfarctionMESH : AgedMESH : Prospective StudiesAngiotensin-Converting Enzyme InhibitorsCoronary Artery DiseaseDiseaseMESH : Cerebrovascular Disorders0302 clinical medicineMedicineLongitudinal StudiesProspective StudiesMESH: Coronary Artery DiseaseMyocardial infarctionCoronary Artery BypassMESH: Treatment OutcomeCause of deathAged 80 and overeducation.field_of_studyMESH: Middle AgedHazard ratioMESH : Platelet Aggregation InhibitorsPrognosisMESH: Case-Control Studies3. Good healthMESH: Myocardial InfarctionMESH: Angiotensin Receptor AntagonistsMESH : Angiotensin-Converting Enzyme InhibitorsCardiology and Cardiovascular MedicineMESH: Percutaneous Coronary InterventionMESH : Case-Control Studiesmedicine.medical_specialtyMESH : Angiotensin Receptor AntagonistsMESH: Prognosis03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedMESH : Coronary Artery DiseaseMESH : Aged 80 and overMESH: Hydroxymethylglutaryl-CoA Reductase InhibitorseducationMESH: Age DistributionAgedMESH: HumansMESH: MortalityProportional hazards modelMESH: Coronary Artery BypassMESH : HumansCase-control studyMESH : Proportional Hazards Modelsmedicine.diseaseMESH : Coronary Artery BypassCase-Control StudiesMESH: FemaleMESH: RegistriesMESH : Age Distribution030204 cardiovascular system & hematologyMESH: AtherosclerosisMESH: Proportional Hazards ModelsMESH: Cause of DeathMESH: Aged 80 and overMESH : Percutaneous Coronary InterventionRisk FactorsMESH: Risk FactorsCause of DeathMESH : FemaleRegistries030212 general & internal medicineMESH: Longitudinal StudiesMESH : Longitudinal StudiesMESH: AgedMESH : PrognosisMESH: Angiotensin-Converting Enzyme InhibitorsMESH: Adrenergic beta-AntagonistsMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsTreatment OutcomeMESH: Platelet Aggregation InhibitorsCardiologyFemaleMESH: Cerebrovascular DisordersFranceMESH : MaleAdrenergic beta-AntagonistsMESH : Adrenergic beta-AntagonistsPopulationMESH : Treatment OutcomeMESH: Multivariate AnalysisAngiotensin Receptor AntagonistsAge DistributionInternal medicineMortalityMESH : FranceProportional Hazards ModelsMESH : Cause of Deathbusiness.industryMESH : Hydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Multivariate AnalysisPercutaneous coronary interventionAtherosclerosisMESH: MaleMESH: Prospective StudiesMESH: FranceCerebrovascular DisordersMultivariate AnalysisHydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Myocardial InfarctionbusinessPlatelet Aggregation InhibitorsMESH : RegistriesThe American Journal of Cardiology
researchProduct

Cardiac rehabilitation and 5-year mortality after acute coronary syndromes: The 2005 French FAST-MI study.

2016

IF 2.271; International audience; Background. - Clinical studies have shown a beneficial effect of cardiac rehabilitation (CR) on mortality.Objective. - To study the effect of CR prescription at discharge on 5-year mortality in patients with acute myocardial infarction (AMI).Methods. - Participants, from the 2005 French FAST-MI hospital registry, were 2894 survivors at discharge, divided according to AMI type: ST-segment elevation myocardial infarction (STEMI; n=1523) and non-STEMI (NSTEMI; n=1371). The effect of CR prescription on mortality was analysed using a Cox proportional hazards model.Results. - At discharge, 22.1% of patients had a CR prescription. Patients referred to CR were youn…

MaleMESH: Chi-Square Distributionmedicine.medical_treatmentMESH : Acute Coronary SyndromeMyocardial InfarctionMESH : AgedMESH : Prospective StudiesCardiac rehabilitationMESH: Risk Assessment0302 clinical medicineMyocardial infarctionProspective StudiesReferral and ConsultationMESH: Treatment OutcomeRehabilitationMESH: Middle AgedGeneral MedicineMESH: Follow-Up Studies3. Good healthMESH: Myocardial InfarctionMESH : Patient DischargeCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute myocardial infarctionMortalitéRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedAcute Coronary SyndromeMESH: Kaplan-Meier EstimateAgedChi-Square DistributionMESH: HumansMESH : Chi-Square DistributionProportional hazards modelMESH: Patient DischargeMESH : HumansPatient survivalMESH : Follow-Up Studiesmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Acute Coronary SyndromeST-segment elevation myocardial infarctionMESH: FemaleTime FactorsMESH: RegistriesKaplan-Meier Estimate030204 cardiovascular system & hematologyMESH : Referral and ConsultationMESH: Proportional Hazards ModelsOlder patientsRisk FactorsMESH: Risk FactorsMESH : Female030212 general & internal medicineRegistriesMESH : Risk AssessmentMESH: AgedEjection fractionNon–ST-segment elevation myocardial infarctionMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsPatient DischargeTreatment OutcomeFemaleFranceMESH : Time FactorsMESH : MaleMESH : Treatment OutcomeMESH: Multivariate AnalysisMESH : Kaplan-Meier EstimateMESH: Referral and ConsultationInternal medicineInfarctus du myocarde sans sus-décalage du segment STmedicineIn patientcardiovascular diseasesMedical prescriptionMortalityRéadaptation cardiaqueMESH : FranceProportional Hazards Modelsbusiness.industryInfarctus du myocarde avec sus-décalage du segment STMESH: Time FactorsMESH : Multivariate AnalysisMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceInfarctus du myocarde aiguMultivariate AnalysisMESH : Myocardial InfarctionbusinessMESH : RegistriesFollow-Up Studies
researchProduct